Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.60
AMGN's Cash to Debt is ranked higher than
53% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. AMGN: 0.60 )
AMGN' s 10-Year Cash to Debt Range
Min: 0.27   Max: 8.25
Current: 0.6

0.27
8.25
Equity to Asset 0.33
AMGN's Equity to Asset is ranked higher than
53% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMGN: 0.33 )
AMGN' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.81
Current: 0.33

0.33
0.81
F-Score: 6
Z-Score: 1.86
M-Score: -2.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 31.41
AMGN's Operating margin (%) is ranked higher than
95% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. AMGN: 31.41 )
AMGN' s 10-Year Operating margin (%) Range
Min: -14.21   Max: 43.12
Current: 31.41

-14.21
43.12
Net-margin (%) 27.21
AMGN's Net-margin (%) is ranked higher than
95% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. AMGN: 27.21 )
AMGN' s 10-Year Net-margin (%) Range
Min: -25.2   Max: 34.22
Current: 27.21

-25.2
34.22
ROE (%) 23.00
AMGN's ROE (%) is ranked higher than
96% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. AMGN: 23.00 )
AMGN' s 10-Year ROE (%) Range
Min: -7.61   Max: 36.26
Current: 23

-7.61
36.26
ROA (%) 7.68
AMGN's ROA (%) is ranked higher than
91% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. AMGN: 7.68 )
AMGN' s 10-Year ROA (%) Range
Min: -5.69   Max: 26.89
Current: 7.68

-5.69
26.89
ROC (Joel Greenblatt) (%) 74.52
AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. AMGN: 74.52 )
AMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24.94   Max: 89.4
Current: 74.52

-24.94
89.4
Revenue Growth (%) 16.10
AMGN's Revenue Growth (%) is ranked higher than
88% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. AMGN: 16.10 )
AMGN' s 10-Year Revenue Growth (%) Range
Min: 5.9   Max: 29.3
Current: 16.1

5.9
29.3
EBITDA Growth (%) 9.20
AMGN's EBITDA Growth (%) is ranked higher than
88% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. AMGN: 9.20 )
AMGN' s 10-Year EBITDA Growth (%) Range
Min: 1.1   Max: 25.3
Current: 9.2

1.1
25.3
EPS Growth (%) 11.50
AMGN's EPS Growth (%) is ranked higher than
88% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. AMGN: 11.50 )
AMGN' s 10-Year EPS Growth (%) Range
Min: 2.3   Max: 28.2
Current: 11.5

2.3
28.2
» AMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AMGN Guru Trades in Q1 2013

Paul Tudor Jones 83,400 sh (+1795.45%)
Manning & Napier Advisors, Inc 180,270 sh (+283.38%)
Ray Dalio 69,597 sh (+141.68%)
Jeremy Grantham 1,932,314 sh (+29.63%)
Jim Simons 945,100 sh (+28.53%)
Tom Russo 100 sh (unchged)
RS Investment Management Sold Out
Brian Rogers Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Bill Frels 12,305 sh (-0.81%)
Mario Gabelli 22,690 sh (-0.87%)
Ken Fisher 6,764 sh (-1.4%)
Vanguard Health Care Fund 11,495,055 sh (-2.24%)
PRIMECAP Management 39,885,427 sh (-5.12%)
Pioneer Investments 1,161,851 sh (-18.6%)
Dodge & Cox 473,372 sh (-38.25%)
John Hussman 500,000 sh (-44.44%)
» More
Q2 2013

AMGN Guru Trades in Q2 2013

Alan Fournier 155,000 sh (New)
Steven Cohen 21,979 sh (New)
Mark Hillman 8,969 sh (New)
Jim Simons 1,274,945 sh (+34.9%)
Ray Dalio 83,244 sh (+19.61%)
Jeremy Grantham 2,066,387 sh (+6.94%)
Tom Russo Sold Out
Ken Fisher 6,413 sh (-5.19%)
PRIMECAP Management 37,348,991 sh (-6.36%)
Vanguard Health Care Fund 10,758,455 sh (-6.41%)
Bill Frels 11,505 sh (-6.5%)
Mario Gabelli 17,660 sh (-22.17%)
Manning & Napier Advisors, Inc 128,897 sh (-28.5%)
Pioneer Investments 712,557 sh (-38.67%)
Dodge & Cox 261,222 sh (-44.82%)
John Hussman 200,000 sh (-60%)
Paul Tudor Jones 6,300 sh (-92.45%)
» More
Q3 2013

AMGN Guru Trades in Q3 2013

Stanley Druckenmiller 231,000 sh (New)
Steven Cohen 63,283 sh (+187.92%)
Jeremy Grantham 2,668,851 sh (+29.16%)
Mario Gabelli 22,420 sh (+26.95%)
John Hussman 250,000 sh (+25%)
Vanguard Health Care Fund 10,758,455 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 696,092 sh (-2.31%)
Bill Frels 11,180 sh (-2.82%)
PRIMECAP Management 35,812,225 sh (-4.11%)
Mark Hillman 8,069 sh (-10.03%)
Ken Fisher 5,632 sh (-12.18%)
Dodge & Cox 160,052 sh (-38.73%)
Alan Fournier 90,000 sh (-41.94%)
Jim Simons 71,000 sh (-94.43%)
Manning & Napier Advisors, Inc 5,241 sh (-95.93%)
» More
Q4 2013

AMGN Guru Trades in Q4 2013

Joel Greenblatt 23,170 sh (New)
Paul Tudor Jones 7,697 sh (New)
Ray Dalio 7,513 sh (New)
Jim Simons 862,245 sh (+1114.43%)
Steven Cohen 751,083 sh (+1086.86%)
Jeremy Grantham 3,122,746 sh (+17.01%)
Mario Gabelli 23,620 sh (+5.35%)
Ken Fisher 5,837 sh (+3.64%)
Stanley Druckenmiller 231,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments 694,971 sh (-0.16%)
PRIMECAP Management 35,508,354 sh (-0.85%)
Mark Hillman 7,912 sh (-1.95%)
Bill Frels 10,780 sh (-3.58%)
Dodge & Cox 136,620 sh (-14.64%)
Vanguard Health Care Fund 8,775,155 sh (-18.43%)
Alan Fournier 70,000 sh (-22.22%)
John Hussman 175,000 sh (-30%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-12-31 Reduce -18.43%0.76%$106.28 - $118.688 $ 115.462%8775155
John Hussman 2013-12-31 Reduce -30%0.45%$106.28 - $118.688 $ 115.462%175000
Joel Greenblatt 2013-12-31 New Buy0.06%$106.28 - $118.688 $ 115.462%23170
Ray Dalio 2013-12-31 New Buy0.01%$106.28 - $118.688 $ 115.462%7513
John Hussman 2013-09-30 Add 25%0.3%$95.81 - $117.521 $ 115.466%250000
PRIMECAP Management 2013-09-30 Reduce -4.11%0.22%$95.81 - $117.521 $ 115.466%35812225
Ray Dalio 2013-09-30 Sold Out 0.07%$95.81 - $117.521 $ 115.466%0
Dodge & Cox 2013-09-30 Reduce -38.73%0.01%$95.81 - $117.521 $ 115.466%160052
Mario Gabelli 2013-09-30 Add 26.95%$95.81 - $117.521 $ 115.466%22420
John Hussman 2013-06-30 Reduce -60%1.14%$94.6 - $113.42 $ 115.4611%200000
PRIMECAP Management 2013-06-30 Reduce -6.36%0.38%$94.6 - $113.42 $ 115.4611%37348991
Vanguard Health Care Fund 2013-06-30 Reduce -6.41%0.29%$94.6 - $113.42 $ 115.4611%10758455
Dodge & Cox 2013-06-30 Reduce -44.82%0.03%$94.6 - $113.42 $ 115.4611%261222
Mario Gabelli 2013-06-30 Reduce -22.17%$94.6 - $113.42 $ 115.4611%17660
John Hussman 2013-03-31 Reduce -44.44%0.89%$82.08 - $102.51 $ 115.4630%500000
Joel Greenblatt 2013-03-31 Sold Out 0.2%$82.08 - $102.51 $ 115.4630%0
Ray Dalio 2013-03-31 Add 141.68%0.04%$82.08 - $102.51 $ 115.4630%69597
Dodge & Cox 2013-03-31 Reduce -38.25%0.03%$82.08 - $102.51 $ 115.4630%473372
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Amgen Inc

Mario Gabelli Comments on Amgen Inc. - Jan 06, 2014

Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales. 

 

From Mario Gabelli (Trades, Portfolio)'s third quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Amgen Inc

Mario Gabelli Comments on Amgen Inc.
Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales.  Read more...
PRIMECAP Trims Top Biotechs and More
Founded in 1983, PRIMECAP Management’s portfolio currently lists 251 stocks, nine of them new, with a total value of $69.9 billion and a quarter-over-quarter turnover of 3%. The portfolio is currently weighted with top three sectors: healthcare at 32.2%, technology at 31.2% and industrials at 13.2%. PRIMECAP Management is a mutual fund firm and the third highest in total value, right below Warren Buffett’s Berkshire Hathaway at $89.03 billion and Dodge & Cox at $84.20 billion. PRIMECAP’s 10-year average return is 9.9%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.40
AMGN's P/E(ttm) is ranked higher than
87% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. AMGN: 17.40 )
AMGN' s 10-Year P/E(ttm) Range
Min: 10.4   Max: 42.21
Current: 17.4

10.4
42.21
P/B 3.80
AMGN's P/B is ranked higher than
68% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AMGN: 3.80 )
AMGN' s 10-Year P/B Range
Min: 1.8   Max: 5.24
Current: 3.8

1.8
5.24
P/S 4.70
AMGN's P/S is ranked higher than
75% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. AMGN: 4.70 )
AMGN' s 10-Year P/S Range
Min: 3.01   Max: 13.13
Current: 4.7

3.01
13.13
PFCF 16.00
AMGN's PFCF is ranked higher than
82% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. AMGN: 16.00 )
AMGN' s 10-Year PFCF Range
Min: 8.78   Max: 51.28
Current: 16

8.78
51.28
EV-to-EBIT 17.20
AMGN's EV-to-EBIT is ranked higher than
63% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. AMGN: 17.20 )
AMGN' s 10-Year EV-to-EBIT Range
Min: 8   Max: 30.4
Current: 17.2

8
30.4
PEG 1.90
AMGN's PEG is ranked higher than
65% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. AMGN: 1.90 )
AMGN' s 10-Year PEG Range
Min: 0.25   Max: 3.15
Current: 1.9

0.25
3.15
Shiller P/E 22.90
AMGN's Shiller P/E is ranked higher than
81% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. AMGN: 22.90 )
AMGN' s 10-Year Shiller P/E Range
Min: 12.63   Max: 99.68
Current: 22.9

12.63
99.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.70
AMGN's Dividend Yield is ranked higher than
75% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. AMGN: 1.70 )
AMGN' s 10-Year Dividend Yield Range
Min: 0.48   Max: 1.89
Current: 1.7

0.48
1.89
Dividend Payout 0.28
AMGN's Dividend Payout is ranked higher than
71% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. AMGN: 0.28 )
AMGN' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.28
Current: 0.28

0.14
0.28
Yield on cost (5-Year) 1.70
AMGN's Yield on cost (5-Year) is ranked higher than
65% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. AMGN: 1.70 )
AMGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.48   Max: 1.89
Current: 1.7

0.48
1.89
Share Buyback Rate 7.40
AMGN's Share Buyback Rate is ranked higher than
98% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. AMGN: 7.40 )
AMGN' s 10-Year Share Buyback Rate Range
Min: 8.3   Max: -7.5
Current: 7.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
AMGN's Price/DCF (Projected) is ranked higher than
94% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. AMGN: 1.00 )
AMGN' s 10-Year Price/DCF (Projected) Range
Min: 0.63   Max: 5.96
Current: 1

0.63
5.96
Price/Median PS Value 1.10
AMGN's Price/Median PS Value is ranked higher than
67% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMGN: 1.10 )
AMGN' s 10-Year Price/Median PS Value Range
Min: 0.81   Max: 4.65
Current: 1.1

0.81
4.65
Price/Peter Lynch Fair Value 2.60
AMGN's Price/Peter Lynch Fair Value is ranked higher than
60% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. AMGN: 2.60 )
AMGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67   Max: 3.1
Current: 2.6

0.67
3.1
Earnings Yield (Greenblatt) 5.80
AMGN's Earnings Yield (Greenblatt) is ranked higher than
69% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. AMGN: 5.80 )
AMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.3   Max: 12.5
Current: 5.8

3.3
12.5
Forward Rate of Return (Yacktman) 10.77
AMGN's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. AMGN: 10.77 )
AMGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.4   Max: 70.3
Current: 10.77

1.4
70.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:AMG.Germany
Amgen Inc., a Delaware corporation was incorporated in 1980. The Company is a biotechnology medicines company. It discovers, develops, manufactures and delivers innovative human therapeutics. Its medicines help patients fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. The Company operates in one business segment which includes human therapeutics. The Company's principal products are: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases. Its marketed products include Sensipar/Mimpara , a small molecule calcimimetic that lowers serum calcium levels; Vectibix , a monoclonal antibody that binds specifically to the epidermal growth factor receptor ; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition to its marketed products, it has various product candidates in mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company's manufacturing operations consist of bulk manufacturing, formulation, fill and finish and distribution activities for all of its principal products as well product candidates. Its manufacturing facilities are located in the United States, Puerto Rico and the Netherlands.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide